Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer.

@article{Andr2005MitoticIA,
  title={Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer.},
  author={Fabrice Andr{\'e} and Ahmed Abd El-Gleil Khalil and Kh{\'e}maies Slimane and Christophe C Massard and Marie Christine Mathieu and St{\'e}phane Vignot and Hazem I Assi and Suzette Delaloge and Marc Spielmann},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 13},
  pages={2996-3000}
}
PURPOSE We have evaluated whether the mitotic index could predict the benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer who are eligible for adjuvant chemotherapy according to Saint Gallen guidelines. PATIENTS AND METHODS A total of 937 patients from a single institution were included in two randomized trials that compared adjuvant anthracycline-based chemotherapy with no chemotherapy. These patients account for 83% of the overall population included in… CONTINUE READING

From This Paper

Topics from this paper.
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…